This week Anne Donohoe and Nick Opich talk to Dr. Joseph Tucker, CEO of Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogen therapeutics for…
Read More
Enveric Biosciences stock rose 162.3% to $2.18 during Thursday’s pre-market session. The company’s market cap stands at $5.9 million. Full Article >>
Enveric Biosciences, a Florida-headquartered biotech company developing novel neuroplasticity-promoting small molecule therapeutics for depression, anxiety and addiction disorders treatment has signed three non-binding term sheets with another (undisclosed) biotechnology company…
Enveric Biosciences Inc. said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, Massachusetts-based company didn’t disclose the amount. The divested portfolio includes patents…
Enveric Biosciences (NASDAQ: ENVB) is selling one of its cancer-related patent portfolios for an undisclosed amount. Enveric said it plans to continue to focus and invest in the development of…
Enveric Biosciences announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI). The compounds span seven distinct molecule…
Joe Tucker, CEO of Enveric Biosciences, discusses the use of neuroplastogen therapies for the treatment of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. Enveric has developed the…
The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the…
As we step into 2024, the biotechnology industry stands at a pivotal point, driven by rapid advancements in technology and shifting market dynamics. The past few years have been transformative,…
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has…
